Bull Case

Robotic-assisted hip and knee demand accelerates as procedure volumes normalize, lifting ZBH above peers with slower elective-recovery exposure.

New product launches and surgeon conversion improve mix and pricing, expanding margins faster than diversified medtech peers with broader legacy portfolios.

International recovery and distributor execution strengthen revenue growth, while peers with heavier U.S. concentration see less geographic upside.

Operating leverage from higher utilization and disciplined SG&A drives EBIT expansion, allowing ZBH to outpace peers on margin recovery despite moderate leverage.

Base Case

Procedure growth remains steady and replacement cycles support mid-single-digit revenue gains, keeping ZBH ahead of slower-growing orthopedic peers.

Margin improvement continues from mix, productivity, and supply-chain normalization, though gains stay below top-tier medtech peers with stronger scale.

Competitive pressure from Stryker and J&J limits share gains, but ZBH preserves its installed-base advantage and stable recurring demand.

Leverage stays manageable as cash generation covers debt reduction, leaving ZBH more resilient than smaller orthopedic peers with weaker balance sheets.

Bear Case

Procedure volumes soften or recovery stalls, reducing elective surgery demand and pressuring ZBH more than peers with broader non-orthopedic exposure.

Competitive launches from Stryker and J&J erode share, slowing revenue growth and limiting ZBH's ability to defend pricing and mix.

Margin gains fade if product adoption disappoints or costs rise, leaving operating profit expansion below peers with stronger innovation cadence.

Higher leverage and only moderate interest coverage constrain flexibility, making ZBH more vulnerable than less levered peers if growth weakens.

Overall Score

ZBH’s forward profile is supported by steady orthopedic demand, margin recovery, and manageable leverage, though peer competition caps upside and keeps downside moderate.